A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease,Expert Review of Clinical Immunology

当前位置： X-MOL 学术 › Expert Rev. Clin. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease
Expert Review of Clinical Immunology ( IF 4.4 ) Pub Date : 2024-01-21 , DOI: 10.1080/1744666x.2023.2279188
Amandeep Salhotra ₁ , Leah Falk ₁ , Gabriel Park ₂ , Karamjeet Sandhu ₁ , Haris Ali ₁ , Badri Modi ₃ , Susanta Hui ₄ , Ryotaro Nakamura ₁

Affiliation

Patients with chronic graft versus host disease (cGVHD) have low circulating regulatory T cells (Tregs). Interleukin-2(IL-2) is a growth factor for Tregs, and clinical trials have explored its use ...

中文翻译：